Á¦¸ñ
[´º½º] Consequences of Delaying, Denying, Limiting, or Refusing FDA Drug Firm Inspection.
³¯Â¥
2014-10-28
±Û¾´ÀÌ
K-GMP
Á¶È¸¼ö
1,377
÷ºÎÆÄÀÏ
¡¾¡¿¢¬©÷3.png
*ÀÌÀü±Û
K-GMP[(ÁÖ)Çѱ¹Áö¿¥ÇÇ] FSMA:Many people are unfamiliar with the requirements and consequences of fail
*´ÙÀ½±Û
K-GMP[(ÁÖ)Çѱ¹Áö¿¥ÇÇ]_2014³â 10¿ù ¼Ò½ÄÁö